https://www.dsru.org/blog/the-dsru-international-working-group-on-new-developments-in-pharmacovigilance/ 2023-03-23T11:59:04+00:00 https://www.dsru.org/wp-content/uploads/2022/11/DSRU_Consultation_Assistance.jpg https://www.dsru.org/blog/is-a-systematic-review-right-for-you/ 2023-03-23T11:59:21+00:00 https://www.dsru.org/wp-content/uploads/2022/12/Flurbiprofen-paper-snapshot.jpg https://www.dsru.org/blog/never-in-the-history-of-the-dsru-has-its-role-been-so-important-to-society/ 2023-03-23T11:59:37+00:00 https://www.dsru.org/wp-content/uploads/2022/05/Saad-Shakir_DSRU.jpg https://www.dsru.org/blog/blog-dsru-global-pharmacovigilance-observatory-an-introduction/ 2023-03-23T11:59:56+00:00 https://www.dsru.org/wp-content/uploads/2022/12/Global-Regs-DSRU_Blog.jpg https://www.dsru.org/blog/blog-12-week-dosing-interval-for-the-two-covid-19-vaccines-in-the-uk-an-analogy/ 2023-03-23T12:00:20+00:00 https://www.dsru.org/wp-content/uploads/2022/09/CoronaVirus_Vaccine_Blog.jpg https://www.dsru.org/blog/blog-decision-regarding-dosing-of-covid-19-vaccines/ 2023-03-23T12:00:36+00:00 https://www.dsru.org/wp-content/uploads/2022/09/CoronaVirus_Vaccine_Blog.jpg https://www.dsru.org/blog/blog-reporting-rate-of-serious-allergic-reactions-with-the-pfizer-biontech-vaccine-to-put-things-in-perspective/ 2023-03-23T12:00:56+00:00 https://www.dsru.org/wp-content/uploads/2022/09/CoronaVirus_Vaccine_Blog.jpg https://www.dsru.org/blog/blog-the-new-sars-cov-2-variant-comments-on-transmission-virulence-and-response-to-covid-19-drugs-and-vaccines/ 2023-03-23T12:04:38+00:00 https://www.dsru.org/wp-content/uploads/2022/09/CoronaVirus_Blog.jpg https://www.dsru.org/wp-content/uploads/2022/05/Saad-Shakir_DSRU_Team.jpg https://www.dsru.org/blog/blog-anaphylaxis-following-immunisation-with-pfizer-biontech-covid-19-vaccine-ae-comments-on-the-pharmacovigilance-and-clinical-aspects-of-the-association/ 2023-03-23T12:05:08+00:00 https://www.dsru.org/wp-content/uploads/2022/09/CoronaVirus_Vaccine_Blog.jpg https://www.dsru.org/blog/blog-anaphylactoid-reactions-with-pfizer-biontech-covid-19-vaccine-pharmacovigilance-perspective-and-public-information-needs/ 2023-03-23T12:05:30+00:00 https://www.dsru.org/wp-content/uploads/2022/09/CoronaVirus_Vaccine_Blog.jpg https://www.dsru.org/wp-content/uploads/2022/05/Saad-Shakir_DSRU_Team.jpg https://www.dsru.org/blog/swift-response-by-regulator-to-anaphylactoid-response-in-two-covid-19-vaccinees/ 2023-03-23T12:05:57+00:00 https://www.dsru.org/wp-content/uploads/2022/09/CoronaVirus_Blog.jpg https://www.dsru.org/wp-content/uploads/2022/05/Saad-Shakir_DSRU_Team.jpg https://www.dsru.org/blog/it-is-essential-to-monitor-the-post-authorisation-safety-and-efficacy-of-new-covid-19-vaccines/ 2023-03-23T12:06:20+00:00 https://www.dsru.org/wp-content/uploads/2022/09/CoronaVirus_Vaccine_Blog.jpg https://www.dsru.org/blog/vaccine-manufacturersae-safety-commitment-emphasises-importance-of-post-authorisation-safety-and-effectiveness-monitoring/ 2023-03-23T12:06:39+00:00 https://www.dsru.org/wp-content/uploads/2022/09/COVID_19_News_Consortium_DSRU_News.jpg https://www.dsru.org/blog/post-authorisation-safety-and-effectiveness-studies-will-complement-the-pre-marketing-studies-for-vaccines-for-covid-19/ 2023-03-23T12:06:57+00:00 https://www.dsru.org/wp-content/uploads/2022/09/COVID_19_News_Consortium_DSRU_News.jpg https://www.dsru.org/blog/how-pharmacovigilance-needs-to-adapt-in-order-to-handle-the-challenges-of-advanced-therapies-and-the-covid-19-pandemic/ 2023-03-23T12:07:16+00:00 https://www.dsru.org/wp-content/uploads/2022/09/CoronaVirus_Vaccine_Blog.jpg https://www.dsru.org/wp-content/uploads/2022/05/Saad-Shakir_DSRU_Team.jpg https://www.dsru.org/blog/cytokine-storm-a-major-killer-in-patients-with-severe-covid-19-infection/ 2023-03-23T12:07:35+00:00 https://www.dsru.org/wp-content/uploads/2022/09/Active_Surveilliance_DSRU_News.jpg https://www.dsru.org/blog/is-the-uk-facing-its-own-opioid-crisis/ 2023-03-23T12:07:51+00:00 https://www.dsru.org/wp-content/uploads/2022/12/Global-Regs-DSRU_Blog.jpg https://www.dsru.org/blog/meds-the-dsru-centre-for-methods-evidence-and-regulations-in-drug-safety/ 2023-03-23T12:08:10+00:00 https://www.dsru.org/wp-content/uploads/2022/05/Saad-Shakir_DSRU.jpg https://www.dsru.org/blog/dsru-consultancy-world-class-science-at-a-not-for-profit-price/ 2023-03-23T12:08:30+00:00 https://www.dsru.org/wp-content/uploads/2022/09/Help_Support_Guidance_Blog.jpg https://www.dsru.org/blog/measuring-the-impact-of-pharmacovigilance/ 2023-03-23T12:08:57+00:00 https://www.dsru.org/wp-content/uploads/2022/12/Sam-and-Saad-DSRU_Blog.jpg https://www.dsru.org/wp-content/uploads/2022/12/Sam-and-Saad-DSRU_Blog.jpg https://www.dsru.org/blog/what-are-the-main-objectives-of-pass-studies-for-risk-management/ 2023-03-23T12:09:22+00:00 https://www.dsru.org/wp-content/uploads/2022/05/Saad-Shakir_DSRU.jpg https://www.dsru.org/blog/designing-studies-for-risk-management-plans-that-are-acceptable-to-european-regulators/ 2023-03-23T12:09:49+00:00 https://www.dsru.org/wp-content/uploads/2022/05/Saad-Shakir_DSRU.jpg https://www.dsru.org/blog/dsru-attends-the-rcgp-annual-conference-in-harrogate/ 2023-03-23T12:10:07+00:00 https://www.dsru.org/wp-content/uploads/2022/12/Winner-Isa-Houwink.jpg https://www.dsru.org/wp-content/uploads/2022/12/Winner-Isa-Houwink.jpg https://www.dsru.org/blog/pharmacovigilance-science-in-the-uk-and-europe-in-the-years-to-come/ 2023-03-23T12:10:27+00:00 https://www.dsru.org/wp-content/uploads/2022/05/Saad-Shakir_DSRU.jpg https://www.dsru.org/wp-content/uploads/2022/05/Saad-Shakir_DSRU_Team.jpg https://www.dsru.org/blog/a-network-of-studies-ae-risk-management-and-risk-minimisation-studies-conducted-by-a-network-of-european-countries/ 2023-03-23T12:10:45+00:00 https://www.dsru.org/wp-content/uploads/2022/12/EU_Flags_DSRU_Blog.jpg https://www.dsru.org/blog/blog-roundup-of-dsru-research-on-covid-19-vaccines-and-treatments/ 2023-12-12T13:08:20+00:00 https://www.dsru.org/wp-content/uploads/2023/02/Coronavirus-purchased300-200.jpg https://www.dsru.org/blog/risk-minimisation-measures-for-isotretinoin/ 2023-12-12T13:43:12+00:00 https://www.dsru.org/wp-content/uploads/2023/12/Isotretinoin_blog.png https://www.dsru.org/blog/benefit-risk-balance-of-codeine-linctus/ 2024-04-08T11:28:34+00:00 https://www.dsru.org/wp-content/uploads/2024/04/benefit-risk_balance_of_codeine_linctus.jpg https://www.dsru.org/blog/thoughts-from-saad-shakir/ 2024-07-03T09:04:23+00:00 https://www.dsru.org/wp-content/uploads/2024/07/DSRU_Saads_Blog-1.jpg https://www.dsru.org/blog/from-the-world-of-pharmacovigilance/ 2024-07-10T10:44:47+00:00 https://www.dsru.org/wp-content/uploads/2024/07/world_of-pharmacovigilance_blog.jpg https://www.dsru.org/blog/benefit-risk-balance/ 2024-08-28T07:43:01+00:00 https://www.dsru.org/wp-content/uploads/2024/07/DSRU_Saad_blog_benefit.jpg https://www.dsru.org/blog/lecanemab-alzheimers-disease/ 2024-08-28T07:56:56+00:00 https://www.dsru.org/wp-content/uploads/2024/08/alzheimers_drug_blog.jpg https://www.dsru.org/blog/licensing-lecanemab-by-the-mhra-in-the-uk/ 2024-09-06T09:31:08+00:00 https://www.dsru.org/wp-content/uploads/2024/09/alzheimes_blog.jpg https://www.dsru.org/blog/ai-multiple-data-sources-in-pharmacovigilance/ 2025-03-20T11:55:46+00:00 https://www.dsru.org/wp-content/uploads/2025/03/AI-Pharmacovigilance-DSRU.jpg https://www.dsru.org/blog/a-milestone-in-the-history-of-medicine-anastrazole/ 2026-07-23T14:07:26+00:00 https://www.dsru.org/wp-content/uploads/2023/11/DSRU-anastrazole.png https://www.dsru.org/blog/returning-to-the-horizon-europe-programme/ 2026-07-23T14:13:56+00:00 https://www.dsru.org/wp-content/uploads/2023/10/DSRU-european.png